Fecal microbiota, live

Brand names: Rebyota
Drug class: Antineoplastic Agents

Usage of Fecal microbiota, live

Fecal microbiota, live-jslm has the following uses:

Fecal microbiota, live-jslm is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. Fecal microbiota, live-jslm is not indicated for the treatment of CDI.

The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) has published guidelines on the management of CDI. The guidelines state that fecal microbiota transplantation (FMT) is recommended only for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments and where appropriate screening of donor and donor fecal specimens has been performed.

Relate drugs

How to use Fecal microbiota, live

General

Fecal microbiota, live-jslm is available in the following dosage form(s) and strength(s):

Suspension: 150 mL of fecal microbiota suspension which contains between 1×108 and 5×1010 colony forming units (CFU) per mL of fecal microbes including >1×105 CFU/mL of Bacteroides.

Dosage

It is essential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration in Adults ≥18 Years of Age
  • For rectal administration only.
  • Prior to use, thaw fecal microbiota, live-jslm completely by placing the carton in a refrigerator, 2°C to 8°C (36°F to 46°F), for approximately 24 hours. The carton may be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and used within 5 days, including thawing time. DO NOT thaw using a heat source such as a microwave or hot water.
  • Administer fecal microbiota, live-jslm 24 to 72 hours after the last dose of antibiotics for CDI.
  • Administer a single dose of 150 mL rectally.
  • Consult the full prescribing information for additional information on preparation and administration of fecal microbiota, live-jslm.
  • Warnings

    Contraindications

  • Severe allergic Reactions (e.g. anaphylaxis) to any component of fecal microbiota, live-jslm.
  • Warnings/Precautions

    Transmissible Infectious Agents

    Because fecal microbiota, live-jslm is manufactured from human fecal matter it may carry a risk of transmitting infectious agents. Any infection suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to the manufacturer.

    Management of Acute Allergic Reactions

    Appropriate medical treatment must be immediately available in the event an acute anaphylactic reaction occurs following administration of fecal microbiota, live-jslm.

    Potential Presence of Food Allergens

    Fecal microbiota, live-jslm is manufactured from human fecal matter and may contain food allergens. The potential for fecal microbiota, live-jslm to cause adverse reactions due to food allergens is unknown.

    Specific Populations

    Pregnancy

    Fecal microbiota, live-jslm is not absorbed systemically following rectal administration, and maternal use is not expected to result in fetal exposure to the drug.

    Lactation

    Fecal microbiota, live-jslm is not absorbed systemically by the mother following rectal administration, and breastfeeding is not expected to result in exposure of the child to fecal microbiota, live-jslm.

    Pediatric Use

    Safety and effectiveness of fecal microbiota, live-jslm in individuals younger than 18 years of age have not been established.

    Geriatric Use

    Of the 978 adults who received fecal microbiota, live-jslm, 48.8% were 65 years of age and over (n=477), and 25.7% were 75 years of age and over (n=251). Data from clinical studies of fecal microbiota, live-jslm are not sufficient to determine if adults 65 years of age and older respond differently than younger adults.

    Common Adverse Effects

    The most commonly reported (≥3%) adverse reactions occurring in adults following a single dose of fecal microbiota, live-jslm were abdominal pain, (8.9%), diarrhea (7.2%), abdominal distention (3.9%), flatulence (3.3%), and nausea (3.3%).

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords